CoChat

Systematic Review and Meta-Analysis of the Efficacy and Safety of Metformin and GLP-1 Analogues in Children and Adolescents with Diabetes Mellitus Type 2

Carydias, Elisabeth, Tasho, Andoneta, Kani, Chara, Bacopoulou, Flora, Stefanaki, Charikleia, Markantonis, Sophia L. · 2022 · Children
Cited by 5

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Diabetes mellitus type 2 (DMT2) is one of the most frequent glucose metabolism disorders, in which serum glucose concentrations are increased. In most cases, changes in lifestyle and diet are considered as the first step in addressing its therapy. If changes in lifestyle and diet fail, drugs, such as metformin, must be added. Lately, apart from metformin or insulin, the FDA has approved the use of glucagon-like peptide-1 (GLP-1) analogues for children and adolescents. Little is known about their efficacy and safety at this young age. The main aim of this systematic review/meta-analysis was to assess the safety and efficacy of metformin and GLP-1 analogues, exenatide and liraglutide, compared with placebos or other antidiabetic drugs used for DMT2 in children and adolescents. Metformin did not seem to demonstrate pharmacologic superiority, while GLP-1 analogues were found superior to placebos. GLP-1 analogues may be considered a useful alternative for the treatment of DMT2 in children and adolescents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/children9101572

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 28

  1. Khan, 2020, Epidemiology of type 2 diabetes—Global burden of disease and forecasted trends, J. Epidemiol. Glob. Health, 10, 107, 10.2991/jegh.k.191028.001 · DOI · Paper page
  2. Stefanaki, C., Michos, A., Mastorakos, G., Mantzou, A., Landis, G., Zosi, P., and Bacopoulou, F. (2019). Probiotics in adolescent prediabetes: A pilot RCT on glycemic control and intestinal bacteriome. J. Clin. Med., 8. · DOI
  3. Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K.B., Ostolaza, H., and Martin, C. (2020). Pathophysiology of type 2 diabetes mellitus. Int. J. Mol. Sci., 21. · DOI · Paper page
  4. Bacopoulou, 2020, Identifying early abdominal obesity risk in adolescents by telemedicine: A cross-sectional study in Greece, Food Chem. Toxicol. Int. J. Publ. Br. Ind. Biol. Res. Assoc., 144, 111532, 10.1016/j.fct.2020.111532 · DOI
  5. Pulungan, 2018, Type 2 diabetes mellitus in children and adolescent: An Indonesian perspective, Ann. Pediatric Endocrinol. Metab., 23, 119, 10.6065/apem.2018.23.3.119 · DOI
  6. Stefanaki, C., Michos, A., Latsios, G., Tousoulis, D., Peppa, M., Zosi, P., Boschiero, D., and Bacopoulou, F. (2020). Sexual dimorphism of heart rate variability in adolescence: A case-control study on depression, anxiety, stress levels, body composition, and heart rate variability in adolescents with impaired fasting glucose. Int. J. Environ. Res. Public Health, 17. · DOI
  7. Stefanaki, 2016, Prediabetes and adolescence—Trends, causes, effects, and screening, US Endocrinol., 12, 94, 10.17925/USE.2016.12.02.94 · DOI
  8. Stefanaki, C., Paltoglou, G., Mastorakos, G., and Chrousos, G.P. (2022). Chronic stress and steatosis of muscles, bones, liver, and pancreas—A review. Horm. Res. Paediatr. · DOI
  9. Bacopoulou, 2018, Disordered eating attitudes and emotional/behavioral adjustment in Greek adolescents, Eat. Weight. Disord., 23, 621, 10.1007/s40519-017-0466-x · DOI
  10. Wu, 2022, Worldwide estimates of incidence of type 2 diabetes in children and adolescents in 2021, Diabetes Res. Clin. Pract., 185, 109785, 10.1016/j.diabres.2022.109785 · DOI · Paper page
  11. Bacha, 2019, FDA approval of GLP-1 receptor agonist (liraglutide) for use in children, Lancet Child Adolesc. Health, 3, 595, 10.1016/S2352-4642(19)30236-6 · DOI
  12. Soliman, 2020, The clinical application of metformin in children and adolescents: A short update, Acta Bio-Med. Atenei Parm., 91, e2020086
  13. Matsuura, 2019, Metformin monotherapy in children and adolescents with type 2 diabetes mellitus in Japan, Diabetol Int., 10, 51, 10.1007/s13340-018-0361-3 · DOI
  14. Gottschalk, 2007, Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: A randomized, single-blind comparative study, Diabetes Care, 30, 790, 10.2337/dc06-1554 · DOI · Paper page
  15. Klein, 2014, Liraglutide’s safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: A randomized, double-blind, placebo-controlled trial, Diabetes Technol. Ther., 16, 679, 10.1089/dia.2013.0366 · DOI · Paper page
  16. Tamborlane, 2019, Liraglutide in children and adolescents with type 2 diabetes, N. Engl. J. Med., 381, 637, 10.1056/NEJMoa1903822 · DOI · Paper page
  17. Guyatt, 2011, GRADE guidelines: 4. Rating the quality of evidence—Study limitations (risk of bias), J. Clin. Epidemiol., 64, 407, 10.1016/j.jclinepi.2010.07.017 · DOI · Paper page
  18. Higgins, 2011, The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials, BMJ, 343, d5928, 10.1136/bmj.d5928 · DOI · Paper page
  19. Guyatt, 2011, GRADE guidelines 6. Rating the quality of evidence—Imprecision, J. Clin. Epidemiol., 64, 1283, 10.1016/j.jclinepi.2011.01.012 · DOI · Paper page
  20. Guyatt, 2011, GRADE guidelines: 7. Rating the quality of evidence—Inconsistency, J. Clin. Epidemiol., 64, 1294, 10.1016/j.jclinepi.2011.03.017 · DOI · Paper page
  21. Guyatt, 2011, GRADE guidelines: 8. Rating the quality of evidence—Indirectness, J. Clin. Epidemiol., 64, 1303, 10.1016/j.jclinepi.2011.04.014 · DOI · Paper page
  22. Guyatt, 2011, GRADE guidelines: 5. Rating the quality of evidence—Publication bias, J. Clin. Epidemiol., 64, 1277, 10.1016/j.jclinepi.2011.01.011 · DOI · Paper page
  23. Sanneh, 2012, Clinical effect of Metformin in children and adolescents with type 2 diabetes mellitus: A systematic review and meta-analysis, J. Fam. Community Med., 19, 68, 10.4103/2230-8229.98279 · DOI
  24. Kuzik, 2015, Evaluating the effects of metformin use on height in children and adolescents: A meta-analysis of randomized clinical trials, JAMA Pediatr., 169, 1032, 10.1001/jamapediatrics.2015.2186 · DOI
  25. Chadda, 2021, GLP-1 agonists for obesity and type 2 diabetes in children: Systematic review and meta-analysis, Obes. Rev., 22, e13177, 10.1111/obr.13177 · DOI · Paper page
  26. Sun, 2015, Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: A systematic review and network meta-analysis, Diabetes Technol. Ther., 17, 35, 10.1089/dia.2014.0188 · DOI · Paper page
  27. Monami, 2009, Glucagon-like peptide-1 receptor agonists in type 2 diabetes: A meta-analysis of randomized clinical trials, Eur. J. Endocrinol., 160, 909, 10.1530/EJE-09-0101 · DOI · Paper page
  28. Temneanu, 2016, Type 2 diabetes mellitus in children and adolescents: A relatively new clinical problem within pediatric practice, J. Med. Life, 9, 235

Cited by

See all 5

Metadata

Authors
Carydias, E., Tasho, A., Kani, C., Bacopoulou, F., Stefanaki, C., & Markantonis, S. L.
Affiliations
  • Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15774 Athens, Greece
  • University Research Institute for the Study of Genetic and Malignant Disorders in Childhood, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
Venue
Children
Publisher
MDPI AG
Published
2022-10-18
Volume
9
Issue
10
Pages
1572
ISSN
2227-9067
Cited by
5
References
7
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systematic Review and Meta-Analysis of the Efficacy and Safety of Metformin and GLP-1 Analogues in Children and Adolescents with Diabetes Mellitus Type 2. https://app.cochat.ai/papers/10.3390/children9101572
The paper
Carydias, E., Tasho, A., Kani, C., Bacopoulou, F., Stefanaki, C., & Markantonis, S. L. (2022). Systematic Review and Meta-Analysis of the Efficacy and Safety of Metformin and GLP-1 Analogues in Children and Adolescents with Diabetes Mellitus Type 2. Children. https://doi.org/10.3390/children9101572

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.